CASP1 and neoplasm: RIG-I agonists can activate the intrinsic immune effector RIG-I in breast cancer cells, increase the immunogenicity of the tumor, activate caspase-1 cleavage of GSDMD in vitro, and are a viable approach for the treatment of breast cancer [109].